Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To the Editor, As T cell-mediated immunotherapies are being explored as a treatment strategy for relapsed and refractory chronic lymphocytic leukemia (CLL), the study of autologous T cells in patients with CLL has intensified [1, 2]. The repertoire of αβ T cell receptors (TRA/TRB repertoire) in CLL patients exhibits several abnormalities.
The sensitivity of conventional techniques for reliable quantification of minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is limited to MRD 10−4. Measuring MRD <10−4 could help to further distinguish between patients with CLL with durable remission and those at risk of early relapse. We herein present an academically developed immunoglobulin heavy-chain variable (IGHV) leader-based next-generation sequencing (NGS) assay for the quantification of MRD in CLL.
The sensitivity of conventional techniques for reliable quantification of minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is limited to MRD 10-4. Measuring MRD <10-4 could help to further distinguish between CLL patients with durable remission and those at risk of early relapse. We here present an academically developed IGHV leader-based next-generation sequencing (NGS) assay for the quantification of MRD in CLL.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
